News For BAYRY From The Last 14 Days Check below for free stories on BAYRY the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 8, 2010
|
| 05:50 EDT |  | BAYRY |
|
|
February 1, 2010
|
| 05:29 EDT |  | BAYRY |
| theflyonthewall.com: | Bayer downgraded to Neutral from Outperform at Exane BNP Paribas | | :theflyonthewall.com |
|
|
January 27, 2010
|
| 21:13 EDT | | BAYRY |
| theflyonthewall.com: | Barrons.com sees five drug candidates boosting their company's sales in 2010 | | According to Decision Resources, drug companies could receive FDA approval for 50 new therapies this year with the potential to generate sales totaling $15B a year by 2015. Some drugs have the ability to shine above the others and boost the bottom lines of the companies that make them. Doctors and industry experts helped Barrons.com find five drug candidates that could hit the U.S. market in 2010, improving the treatment of serious illnesses. The list includes Novo Nordisk's (NVO) diabetes drug, Victoza, and Dendreon's (DNDN) prostate cancer therapy, Provenge. Then there's Vivus' (VVUS) obesity treatment, Qnexa, and Amgen's (AMGN) remedy for osteoporosis, Prolia. Finally, Johnson & Johnson (JNJ) and Bayer (BAYRY) hope to jointly market a blood thinner, Xarelto. Bottom-line: these five drugs could be what the doctor ordered for a sales-starved industry and investors looking for returns. Reference Link :theflyonthewall.com |
|
|
|
Subscribe for More Information